|5.||Venous Thrombosis (Deep-Vein Thrombosis)
|1.||Lip, Gregory Y H: 40 articles (10/2015 - 09/2004)|
|2.||Wallentin, Lars: 39 articles (01/2016 - 09/2009)|
|3.||Halperin, Jonathan L: 29 articles (12/2015 - 03/2004)|
|4.||Singer, Daniel E: 28 articles (12/2015 - 11/2003)|
|5.||Hankey, Graeme J: 28 articles (12/2015 - 05/2005)|
|6.||Connolly, Stuart J: 27 articles (12/2015 - 11/2006)|
|7.||Mahaffey, Kenneth W: 26 articles (12/2015 - 06/2008)|
|8.||Fox, Keith A A: 25 articles (12/2015 - 06/2008)|
|9.||Patel, Manesh R: 25 articles (12/2015 - 06/2008)|
|10.||Piccini, Jonathan P: 24 articles (12/2015 - 06/2008)|
|1.||Warfarin (Coumadin)FDA LinkGeneric
12/01/2008 - "To evaluate the efficacy of warfarin in preventing systemic embolism (embolism to limbs or viscera) in patients with AF. "
08/01/2012 - "The purpose of this study was to assess the risk and timing of thrombo-embolism after warfarin treatment interruption. "
05/01/2013 - "The risk reduction for systemic embolism with new OACs as compared with warfarin in patients with AF is similar to that seen with warfarin (odds ratio 0.79, 95% CI 0.38-1.64). "
07/01/2011 - "Anticoagulation with warfarin if started after surgery would have reduced the risk of embolism in this patient."
01/01/2011 - "She takes warfarin for a pulmonary embolus that occurred 2 months prior. "
08/01/1988 - "Two patients had pulmonary embolus treated successfully with anticoagulants. "
04/01/1978 - "Use of prosthetic valves, despite constant improvement in their manufacture and systematic administration of anticoagulant drugs, are always complicated by embolisms (4 to 7% of cases at present). "
06/15/1993 - "The value of anticoagulants has been demonstrated by large controlled studies, but it is important to know that a very strong anticoagulant treatment is unnecessary to reduce the risk of embolism. "
08/16/1969 - " incidence of recurrent embolism in the trial group is significantly lower than that found in a retrospective study of 50 patients treated with anticoagulants only. "
01/01/2015 - "Anticoagulants were associated with a lower risk of embolism (OR = 0.616, 95% CI = 0.392-0.966, P = 0.04), and this finding persisted in patients with NRAF (OR = 0.581, 95% CI 0.359-0.941, P = 0.03). "
|3.||Aspirin (Acetylsalicylic Acid)FDA LinkGeneric
12/01/2010 - "In patients presenting RMVD with AF for less than a year and no previous embolism, Aspirin is little effective in preventing TE. "
06/01/2014 - "Aspirin has been used as antiplatelet agent, but when the data from two trials the ASPIRE and WARFASA study were pooled, there was a 32% reduction in the rate of recurrence of venous thrombo-embolism and a 34% reduction in the rate of major vascular events. "
09/03/2003 - "Embolism is a major complication of IE, and studies in animal models have shown that platelet inhibition with aspirin can lead to more rapid vegetation resolution and a lower rate of embolic events. "
05/28/2014 - "COM reduced pulmonary embolus mortality by 27, 40 and 53%, vs. 47% for aspirin. "
07/01/2013 - "Antiplatelets, especially aspirin, are prescribed because of a possible preventive effect on embolisms. "
|4.||Heparin (Liquaemin)FDA LinkGeneric
06/01/1982 - "Heparin led to a greater reduction in embolus weight compared to control animals, but in the short time interval of this study it did not lead to improvement, in the respiratory or haemodynamic parameters. "
01/01/2001 - "There is some doubt that heparin is effective for the prevention of systemic embolism in patients with mechanical heart valves. "
12/01/1999 - "Heparin and oral anticoagulation have been shown to be effective in reducing recurrence and death in venous thrombo-embolism. "
11/01/1998 - "There is some doubt that heparin is effective for the prevention of systemic embolism in patients with mechanical heart valves. "
11/01/1998 - "There is a concern about the efficacy of unfractionated heparin in the prevention of arterial embolism in pregnant women with mechanical heart valves. "
09/01/2015 - "She was discharged home on rivaroxaban for prevention of thrombo-embolism. "
09/01/2013 - "Rivaroxaban (with initial increased dosage) may be used as a stand-alone therapy in patients with venous thrombo-embolism. "
06/01/2013 - "Food and Drug Administration (FDA)' approved dabigatran and rivaroxaban for prevention of systemic embolism in non-valvular AF patients. "
10/01/2012 - "All patients admitted with pelvic fractures in a 12-month period followed a standardized thromboprophylaxis protocol: 1) rivaroxaban 10 mg/day within 24 h of injury or upon hemodynamic stability; 2) pre-operative, post-operative, and 30-day extremity ultrasound; 3) ventilation-perfusion scintigraphy for clinical signs of pulmonary embolus; and 4) a 45-, 90-, and 120-day re-evaluation. "
08/01/2012 - "Dabigatran (150 mg bid) showed superior efficacy in preventing ischemic stroke plus systemic embolism to dabigatran (110 mg bid, P=0.0364) and rivaroxaban (P=0.0388). "
04/01/2012 - "This economic evaluation suggests that the use of dabigatran etexilate as a first-line treatment for the prevention of stroke and systemic embolism is likely to be cost-effective in eligible UK patients with AF."
05/01/2011 - "This study demonstrates that dabigatran etexilate is a highly cost-effective alternative to current care for the prevention of stroke and systemic embolism among Canadian AF patients."
07/01/2013 - "Dabigatran etexilate may represent a cost-effective option for the prevention of thromboembolic events in AF patients at moderate-to-high risk of stroke or systemic embolism."
12/01/2010 - "Indirect evidence suggests treatment with dabigatran etexilate offers benefit for the prevention of stroke, systemic embolism and mortality over antiplatelets and placebo. "
12/01/2010 - "Compared with placebo, dabigatran etexilate 150 mg BID was estimated to significantly reduce the risk of any stroke (ischaemic and haemorrhagic) by 75% (relative risk [RR] 0.25; 95% confidence interval [CI] 0.12-0.51), ischaemic stroke by 77% (RR 0.23; 95% CI 0.14-0.38), systemic embolism by 83% (RR 0.17; 95% CI 0.05-0.50) and mortality by 36% (RR 0.64; 95% CI 0.45-0.91). "
|7.||glucuronyl glucosamine glycan sulfate (Vessel)IBA
06/01/2002 - "DSA was one of the best ways to make a correct diagnosis of TCCF and intra-vessel embolism, to give a successful therapy."
10/01/2006 - "Surgical removal of the embolus was achieved in six of the seven (87.5%) patients, visual acuity improved from a median of 20/400 (range: hand movements 20/25) to 20/40 (range: hand movements 20/25), and reperfusion of the occluded vessel was angiographically confirmed in four of the six patients in whom the embolus was successfully removed. "
01/01/1994 - "Using two different frequencies, the vessel geometry (diameter and sample volume length) and per cent hematocrit can be eliminated from calculation of embolus size. "
07/01/2015 - "Each clot (2 cm long) was recanalized within 7 min. The size of the flow channels increased by using higher P- and was significantly larger by using the 0.3 mm scan interval than those using 0.7 mm. The results in this study show the potential of this new microtripsy thrombolysis method for fast, precise, and effective clot recanalization, minimizing risks of vessel damage and embolism. "
09/01/2015 - "From a vessel-based perspective, MRI exhibits a high diagnostic capability with proximal arteries, but lacks sensitivity for peripheral embolism."
|8.||Urokinase-Type Plasminogen Activator (Urokinase)FDA Link
07/01/1993 - "A successful therapy with urokinase of a complete occlusion of the right pulmonary artery by an embolus originating from the right atrium is described in a premature infant. "
09/01/1997 - "To evaluate the efficacy of intraarterial urokinase in the treatment of superior mesenteric arterial (SMA) embolism. "
11/01/1988 - "One was effectively treated with small local doses of urokinase and mechanical fragmentation of the embolus. "
06/21/1996 - "After the urokinase dosage had been raised to 200,000 IU/h TOE on the 6th day no longer showed the embolus and documented a reduction in right-heart dilatation associated with improved haemodynamics. "
05/01/1990 - "Local transcatheter intraarterial administration of urokinase can be considered a first-line treatment for brachial artery embolus and other causes of acute upper-extremity arterial occlusion."
|9.||Vitamin KFDA Link
02/01/2009 - "Despite the use of anti-vitamin K during the first trimester with 42.86% of the patients, the anticoagulation was effective with the entire cases excepted one who died by lung embolism. "
03/01/2009 - "The current approach for deciding the duration of vitamin K antagonist (VKA) treatment after an episode of venous thrombo-embolism (VTE) is mainly based on the characteristic of the index event (3 months or longer in case of unknown/persistent risk factors, 3 months or less in case of removable causes). "
09/01/2004 - "We also recommend systemic anticoagulation with UFH followed by long-term vitamin K antagonist (VKA) in patients with embolism [Grade 1C]). "
10/01/2002 - "Prevention of embolism has for many years been obtained with vitamin K antagonists for which the clinical evidence is overwhelming. "
08/01/2012 - "For the last 50 years, long-term anticoagulation with vitamin K antagonists has been the most effective therapy for preventing stroke and systemic embolism in patients with AF and other risk factors, but their use has a lot of limitations and drawbacks (frequent monitoring and dose adjustment, food and drug interactions, delayed onset of action etc). "
01/01/2014 - "Comparing indirectly BID vs QD dosing regimens resulted in hazard ratios (HR [95% confidence interval]) for stroke and systemic embolism of 0.75 (0.58-0.96) for dabigatran 150 mg BID, and 0.91 (0.73-1.13) for apixaban BID vs the QD dosing regimen. "
12/10/2013 - "The effects of apixaban were similar among patients with and without prior CAD on reducing stroke or systemic embolism and death from any cause (hazard ratio [HR] 0.95, 95% confidence interval [CI] 0.71-1.27, P for interaction=0.12; HR 0.96, 95% CI 0.81-1.13, P for interaction=0.28). "
06/01/2013 - "In conclusion, although longer-term efficacy and safety data are needed, apixaban is an important new option for use in patients with nonvalvular AF to reduce the risk of stroke or systemic embolism."
01/01/2016 - "The effect of apixaban on stroke or systemic embolism in COPD patients was consistent with its effect in the overall trial population."
01/01/2015 - "Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial."
04/01/1988 - "If the embolus is recent, intraarterial fibrinolytic treatment or percutaneous embolectomy can be attempted, but these techniques are not of proven efficacy. "
05/01/2005 - "An aggressive approach to large pulmonary embolus, including rapid diagnosis and prompt surgical intervention, has improved results with surgical embolectomy. "
01/01/1992 - "Mean long term survival in the embolus group was 35 months (range 1-108 months) with a high mortality rate in the first 6 months after embolectomy and improved survival after this. "
09/01/1976 - "It was observed that embolectomy carried out at 2, 3, and up to 5 hours after embolism was relatively safe and effective. "
11/17/1964 - "[HAS TRANSSTERNAL EMBOLECTOMY IMPROVED THE SURGICAL PROGNOSIS IN FULMINATING LUNG EMBOLISM?]."
01/01/2016 - "In this AIS embolism flow model with Solitaire thrombectomy, the Lazarus Funnel resulted in a significant increase in recanalization and significant reduction in distal emboli without increase in time to recanalization."
12/01/2015 - "The Spider filter EPD can be safe and effective in protecting patients from distal branch embolism when they undergo an endovascular thrombectomy procedure."
10/01/2003 - "Although insertion of the device into the SMA via a femoral puncture is a difficult approach, we propose that hydrodynamic thrombectomy followed by local thrombolysis is a useful treatment for acute superior mesenteric artery embolism."
11/01/1985 - "The efficacy of conventional anticoagulation and surgical thrombectomy in controlling embolism and the risk of creating emboli during thrombectomy were also evaluated. "
07/01/2015 - "Successful thrombectomy for coronary embolism likely due to floating aortic plaque in ascending aorta."
|3.||Angioplasty (Angioplasty, Transluminal)
09/01/2011 - "We report a case where use of this novel device helped in achieving a successful angioplasty outcome along with evacuation of distal embolus and restoration of antegrade flow."
11/01/1996 - "[A case of acute occlusion of left middle cerebral artery due to an embolus treated successfully with percutaneous transluminal angioplasty]."
01/01/1986 - "This technique is effective for the treatment of arterial embolism resulting from angioplasty in selected situations."
12/01/2003 - "The system is feasible, safe, and effective for distal protection against embolism during primary angioplasty in AMI."
06/01/2007 - "To evaluate and compare the efficacy of proximal versus distal embolus protection devices (EPD) during carotid artery angioplasty/stenting (CAS) based on diffusion-weighted magnetic resonance imaging (DW-MRI). "
05/01/2002 - "The Medos cannula provides improved hydrodynamic characteristics, probably reducing the risk of atherosclerotic embolism and cerebral malperfusion by avoidance of high back pressures and sandblasting effect."
10/01/2014 - "To investigate the efficacy of catheter aspiration or combined with thrombolysis in the treatment of superior mesenteric artery embolism(SMAE). "
02/01/2008 - "Most data on port catheter embolization consist of isolated case reports; only a few studies have examined a large number of patients with port catheter embolism. "
05/01/1998 - "The course of the radiopaque spot that emerged from the catheter tip within 160 msec was monitored with digital subtraction angiography at a frame rate of 12.5 frames/sec. In two dogs, the study was repeated after embolus fragmentation with the same catheter position. "
01/01/2016 - "Stratified block randomization was performed following embolus injection into one of three cohorts: Solitaire stentriever plus guide catheter (control); control plus proximal Funnel placement; or control plus distal Funnel placement. "
09/01/2013 - "The purpose of this study was to evaluate the influence of stent design on the incidence of procedural and postprocedural embolism associated with CAS treatment. "
06/01/2008 - "Because the in-stent lesion had vanished in the repeat study after recognition of this embolic event, it was suggested that an embolus had been liberated from the in-stent lesion, reaching the left MCA and obliterating it. "
04/16/2004 - "Study of carotid stent implantation with embolism protection was given the award]."
10/01/2015 - "In each group, type of stent during CAS had no significant effect on number of periprocedural embolisms. "
08/18/2015 - "The other 13 cases received endovascular embolism, in which balloon assistant technology was performed in 3 cases and stent assistant technology in another 3 cases. "